{"id":"dx-2930","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding events"},{"rate":null,"effect":"Gastrointestinal adverse events"}]},"_chembl":{"chemblId":"CHEMBL580559","moleculeType":"Small molecule","molecularWeight":"234.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DX-2930 selectively inhibits Factor XIIa (activated Factor XII), a key enzyme in the intrinsic coagulation pathway. By blocking this contact pathway component, the drug reduces pathological clot formation while preserving normal bleeding responses mediated by tissue factor pathway. This selective mechanism aims to provide antithrombotic benefit with reduced bleeding risk compared to conventional anticoagulants.","oneSentence":"DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:24.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombotic disorders / thromboprophylaxis (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07263685","phase":"","title":"A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Hereditary Angioedema (HAE)","enrollment":50},{"nctId":"NCT07445087","phase":"","title":"A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-05-01","conditions":"Hereditary Angioedema (HAE)","enrollment":35},{"nctId":"NCT07251933","phase":"","title":"A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-02-05","conditions":"Hereditary Angioedema (HAE)","enrollment":40},{"nctId":"NCT05397431","phase":"","title":"A Survey of Lanadelumab in Participants With Hereditary Angioedema","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-05-30","conditions":"Hereditary Angioedema (HAE)","enrollment":155},{"nctId":"NCT06346899","phase":"","title":"A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-07-20","conditions":"Hereditary Angioedema (HAE)","enrollment":115},{"nctId":"NCT05297786","phase":"PHASE2","title":"Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-07-27","conditions":"Hemodialysis Complication, Hypotension of Hemodialysis","enrollment":28},{"nctId":"NCT05469789","phase":"","title":"A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-06-29","conditions":"Hereditary Angioedema (HAE)","enrollment":50},{"nctId":"NCT04130191","phase":"","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II","status":"COMPLETED","sponsor":"Shire","startDate":"2019-12-11","conditions":"Hereditary Angioedema (HAE)","enrollment":140},{"nctId":"NCT05147181","phase":"","title":"A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-03-11","conditions":"Hereditary Angioedema (HAE)","enrollment":48},{"nctId":"NCT06818474","phase":"PHASE4","title":"Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","status":"RECRUITING","sponsor":"Bernstein Clinical Research Center","startDate":"2024-06-01","conditions":"Angioedema","enrollment":5},{"nctId":"NCT05460325","phase":"PHASE3","title":"A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-22","conditions":"Hereditary Angioedema (HAE)","enrollment":20},{"nctId":"NCT04444895","phase":"PHASE3","title":"A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor","status":"COMPLETED","sponsor":"Shire","startDate":"2021-02-05","conditions":"Angioedema","enrollment":73},{"nctId":"NCT04848272","phase":"PHASE1","title":"Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"St Vincent's Institute of Medical Research","startDate":"2021-08-09","conditions":"Lung Injury","enrollment":48},{"nctId":"NCT04597944","phase":"","title":"Lanadelumab in Bradykinin Angioedema","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2020-09-18","conditions":"Angioedema","enrollment":80},{"nctId":"NCT04278885","phase":"PHASE2","title":"Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2020-10-05","conditions":"Hereditary Autoinflammatory Disease","enrollment":4},{"nctId":"NCT04206605","phase":"PHASE3","title":"A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-04","conditions":"Angioedema","enrollment":77},{"nctId":"NCT04955964","phase":"","title":"A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-07-28","conditions":"Angioedemas, Hereditary","enrollment":48},{"nctId":"NCT04583007","phase":"","title":"Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults","status":"NO_LONGER_AVAILABLE","sponsor":"Shire","startDate":"","conditions":"Hereditary Angioedema (HAE), Angioedema","enrollment":""},{"nctId":"NCT04687137","phase":"PHASE3","title":"Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-02-10","conditions":"Hereditary Angioedema","enrollment":12},{"nctId":"NCT03845400","phase":"","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America","status":"COMPLETED","sponsor":"Shire","startDate":"2019-03-30","conditions":"Hereditary Angioedema (HAE)","enrollment":168},{"nctId":"NCT04861090","phase":"","title":"A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-09-15","conditions":"Hereditary Angioedema (HAE)","enrollment":207},{"nctId":"NCT04180163","phase":"PHASE3","title":"Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-12-12","conditions":"Hereditary Angioedema (HAE)","enrollment":12},{"nctId":"NCT04590586","phase":"PHASE3","title":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-24","conditions":"COVID-19","enrollment":515},{"nctId":"NCT04070326","phase":"PHASE3","title":"A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children","status":"COMPLETED","sponsor":"Shire","startDate":"2019-08-19","conditions":"Hereditary Angioedema","enrollment":21},{"nctId":"NCT04503603","phase":"PHASE1","title":"A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-08-10","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT04422509","phase":"PHASE1, PHASE2","title":"Lanadelumab for Treatment of COVID-19 Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-10-30","conditions":"COVID-19","enrollment":43},{"nctId":"NCT02741596","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","status":"COMPLETED","sponsor":"Shire","startDate":"2016-05-26","conditions":"Hereditary Angioedema (HAE)","enrollment":212},{"nctId":"NCT03401671","phase":"PHASE1","title":"Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2018-01-15","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02586805","phase":"PHASE3","title":"Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","status":"COMPLETED","sponsor":"Shire","startDate":"2016-03-03","conditions":"Hereditary Angioedema (HAE)","enrollment":125},{"nctId":"NCT02093923","phase":"PHASE1","title":"A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants","status":"COMPLETED","sponsor":"Shire","startDate":"2014-05-14","conditions":"Hereditary Angioedema (HAE)","enrollment":38},{"nctId":"NCT01923207","phase":"PHASE1","title":"A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2013-08-12","conditions":"Hereditary Angioedema (HAE)","enrollment":32},{"nctId":"NCT03918239","phase":"PHASE1","title":"A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.","status":"COMPLETED","sponsor":"Shire","startDate":"2019-05-14","conditions":"Healthy Volunteers","enrollment":190},{"nctId":"NCT04460105","phase":"PHASE1","title":"Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"Shire","startDate":"2020-10-31","conditions":"COVID-19 Pneumonia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DX-2930","genericName":"DX-2930","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis. Used for Thrombotic disorders / thromboprophylaxis (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}